期刊
EXPERT REVIEW OF RESPIRATORY MEDICINE
卷 5, 期 6, 页码 809-821出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/ERS.11.76
关键词
16S ribosomal RNA; asthma; COPD; cystic fibrosis; microbiota; next-generation sequencing; PhyloChip
资金
- NIH [1K23HL105572, AI075410, A113916]
- Cystic Fibrosis Foundation PACE
- Cystic Fibrosis Foundation
Until recently, relationships between evidence of colonization or infection by specific microbial species and the development, persistence or exacerbation of pulmonary disease have informed our opinions of airway microbiology. However, recent applications of culture-independent tools for microbiome profiling have revealed a more diverse microbiota than previously recognized in the airways of patients with chronic pulmonary disease. New evidence indicates that the composition of airway microbiota differs in states of health and disease and with severity of symptoms and that the microbiota, as a collective entity, may contribute to pathophysiologic processes associated with chronic airway disease. Here, we review the evolution of airway microbiology studies of chronic pulmonary disease, focusing on asthma, chronic obstructive pulmonary disease and cystic fibrosis. Building on evidence derived from traditional microbiological approaches and more recent culture-independent microbiome studies, we discuss the implications of recent findings on potential microbial determinants of respiratory health or disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据